The recently discovered (1976) Ebola virus is responsible for one type of human hemorrhagic fever on the African continent (10) . The virus is highly pathogenic, and no vaccine is available; therefore, it is classified as a class 4 viral agent (2) . We initiated a program to investigate the ecology, biology, immunology, and chemistry of this virus and its relatives, and have recently reported on the RNA and protein composition of purified Ebola virions (9, 14) . These studies and others have indicated that this virus possesses unique properties which may qualify it for consideration as a member of a new family of animal viruses. To facilitate further studies, we developed a rapid, quantitative test to measure viral infectivity and antibodies. Several assays have been described for negative-strand viruses (1, 3, 4, 6-8, 12, 16) and were considered for the needs described above. These include hemagglutination, plaque formation, noncytopathic hemadsorption plaques, and immunoperoxidase staining, among others. Although the plaque assay recently reported for Ebola virus (11) is quantitative, we were unable to obtain consistent results. In addition, it requires at least 1 week to obtain results with this assay.
Immunofluorescence assay techniques for viruses have been widely used. An immunofluorescence focus assay for adenoviruses 1, 2, and 12, adeno-associated virus type 1, and reovirus type 1 used human amnion cells (17) . Fluorescent cell counting has been used as an assay for respiratory syncytial virus (15) . In addition, extensive studies using immunofluorescence focus assay techniques have been carried out with persistent mumps virus infections and other agents (18, 19 (9, 14) . This strain was originally isolated in Vero cells, and the viral stock used in this study was from the third passage in Vero cells. The Ebola antiserum used to detect the foci of virusinfected cells was human convalescent-phase serum. Lassa virus and its corresponding antisera used in these experiments have been described previously (21 (21) . Briefly, the cells were stained with convalescent-phase serum for 0.5 h, rinsed thoroughly three times with PBS, and stained for an additional 0.5 h with fluorescein-conjugated anti-human immunoglobulin. After being rinsed, the cells were stained with Evans blue. For quantitation of viral foci, the number of microscopic fields per petri dish was determined with an ocular micrometer.
Conventional cytopathology and immunofluorescence assays. Conventional assays (9, 14, 21) were performed in parallel with the IFU assay. For the cytopathic effect (CPE) assay, Vero cells were grown to confluency in screw-capped tubes, the medium was replaced with fresh medium, 10-fold dilutions of viral inoculum were added, and the cultures were incubated for 7 days. Any cultures demonstrating CPE were designated as positive. Titers were calculated by the method of Reed and Muench (13) .
For the fluorescent antibody (FA) assay, cells in those cultures lacking evidence of microscopic CPE were scraped off, placed on a glass slide, and allowed to air dry. The cells were fixed for 5 min in acetone and stained with antiserum as described above. Any tubes demonstrating specific immunofluorescence were designated as positive, and titers were calculated by the method of Reed and Muench (13) .
RESULTS AND DISCUSSION
When infected cells were examined at 48 h postinfection, foci similar to that shown in Fig. 1   FIG. 1 were observed. The foci were easily detectable and involved few cells. Background staining was virtually absent. Because of the ease of determining the number of infected cells per focus, this method may be useful in estimating the viral growth rate (i.e., each concentric ring of infected cells should approximate one complete replicative cycle).
To determine whether the dose-response curve for this assay was linear, cells were infected with 10-fold dilutions of Ebola and Lassa viruses and assayed as described above. The dose-response curve was indeed linear at the viral concentrations tested (Fig. 2) .
The IFU assay was compared with two conventional assays (FA and CPE) used to titrate Ebola virus. The comparison of IFU, FA, and CPE assays represents the titers of one representative Ebola virus sample, with titers determined from 1:10 to extinction; the quadruplicate samples for each assay type were taken from the same titration, and all three assays were done simultaneously. The Ebola virus titers (average of quadruplicate samples) obtained with the IFU, FA, and CPE assays were 5.8 x 106, 2.0 x 106, and 3.2 x 105 per ml, respectively. Other replicated titrations were carried out, and the results agreed with those described in this analysis. These results indicated that the IFU assay was at least as sensitive as tube titration using immunofluorescence and 10-fold more sensitive than tube titration using CPE to determine the endpoint. When the IFU assay was used to quantitate Lassa virus infection, its sensitivity was similar to that of the plaque assay (data not shown). Previous reports have documented the specificity of the antisera used to detect both Lassa and Ebola virus antigens (20, 21 ).
Although we have described indirect immunofluorescent staining throughout this report, the assay can also be performed by using a direct immunofluorescence technique. We have also determined that the IFU assay works well when Vero cells are used in place of HeLa-229 cells (data not shown).
The results presented here demonstrate that the IFU assay is a sensitive method for titration of Ebola and Lassa viruses. The advantages of this assay over other assays are its speed (2 days versus 5 days or longer) and applicability to a variety of cell lines and viruses. The latter advantage is due to the fact that the assay requires only antigen production and not cell destruction. A potential disadvantage is that the assay might be time consuming when one examines large numbers of samples, especially samples that have low titers (e.g., <102 per ml).
This assay has been used in experiments designed to determine the minimum length of the Ebola virion (Regnery et al., manuscript in preparation), in RNA infectivity studies (14) , in neutralization experiments, and for determining titers of a variety of viral preparations. The sensitivity and specificity of the assay should be improved by the use of high-titered monoclonal antibodies to Ebola virus that we have recently produced.
